Liang Cheng: Advancements in biomarkers and molecular diagnostics in HR+ Breast Cancer
Liang Cheng, Vice Chair for Translational Research at The Warren Alpert Medical School of Brown University, posted on X about recent paper by him as co-author, titled “Recent advancements in biomarkers and molecular diagnostics in hormonal receptor-positive breast cancer” published on Wiley.
Authors: Yihong Wang, Liu Liu, Stephanie L. Graff, Liang Cheng
“Happy Friday! Happy Holidays! I’m delighted to share this insightful review article, published this week in Histopathology, authored by Professor Yihong Wang and colleagues, Congratulations!
Summary: Recent advances in breast cancer research are unlocking new molecular applications for diagnosis and treatment. Personalized therapies like CDK4/6 inhibitors, immune checkpoint inhibitors, and PIK3CA inhibitors are reshaping care for hormone receptor-positive, HER2-negative cancers. Biomarkers related to drug resistance and the tumor microenvironment (TILs, PD-L1) are essential for treatment decisions. Integrating molecular data with pathology will lead to more accurate diagnoses and better outcomes.”
Liang Cheng is a Professor and Vice Chair for Translational Research at The Warren Alpert Medical School of Brown University. He serves as the Director of Anatomic Pathology and Molecular Pathology at Lifespan Academic Medical Center. His research is focused on translational studies of genitourinary cancers and the molecular diagnostics of solid tumors.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023